Cargando…
Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases
BACKGROUND: The treatment of canine chronic cutaneous lupus erythematosus (CCLE) variants generally requires immunosuppression, which often results in potentially severe adverse effects. Janus kinase inhibitors, like oclacitinib, might be a valuable treatment option due to their rapid inhibition of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092348/ https://www.ncbi.nlm.nih.gov/pubmed/36229964 http://dx.doi.org/10.1111/vde.13128 |
_version_ | 1785023323732705280 |
---|---|
author | Harvey, Richard G. Olivrī, Alla Lima, Tatiana Olivry, Thierry |
author_facet | Harvey, Richard G. Olivrī, Alla Lima, Tatiana Olivry, Thierry |
author_sort | Harvey, Richard G. |
collection | PubMed |
description | BACKGROUND: The treatment of canine chronic cutaneous lupus erythematosus (CCLE) variants generally requires immunosuppression, which often results in potentially severe adverse effects. Janus kinase inhibitors, like oclacitinib, might be a valuable treatment option due to their rapid inhibition of the action of interferons known to be relevant in the pathogenesis of CCLE. OBJECTIVES: To report the efficacy and safety of oral oclacitinib for the treatment of canine CCLE variants. ANIMALS: Seven dogs were diagnosed with CCLE based on clinical signs and compatible histopathological findings. MATERIALS AND METHODS: Oclacitinib was administered at the induction dosage of 0.45 mg/kg twice daily to 1.8 mg/kg once daily. The response to treatment was graded as ‘good’ when there was ≥50% lesion reduction, or as ‘complete remission’ if all active lesions had resolved. Complete blood counts were performed at variable intervals. RESULTS: A complete remission of all lesions was obtained in the dog with exfoliative cutaneous lupus erythematosus, both dogs with mucocutaneous lupus erythematosus and three of four dogs with facial discoid lupus erythematosus (FDLE); a good response was seen in the remaining dog with FDLE. The first visible improvement of signs was seen within 2‐to‐3 weeks, while the time to complete remission was around 2 months. Clinical adverse effects were not seen, and haematological parameters remained within the reference range. CONCLUSIONS AND CLINICAL RELEVANCE: Oclacitinib may be considered an effective treatment option for different variants of canine CCLE. |
format | Online Article Text |
id | pubmed-10092348 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100923482023-04-13 Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases Harvey, Richard G. Olivrī, Alla Lima, Tatiana Olivry, Thierry Vet Dermatol Auto‐immune and Immune‐Mediated Dermatoses BACKGROUND: The treatment of canine chronic cutaneous lupus erythematosus (CCLE) variants generally requires immunosuppression, which often results in potentially severe adverse effects. Janus kinase inhibitors, like oclacitinib, might be a valuable treatment option due to their rapid inhibition of the action of interferons known to be relevant in the pathogenesis of CCLE. OBJECTIVES: To report the efficacy and safety of oral oclacitinib for the treatment of canine CCLE variants. ANIMALS: Seven dogs were diagnosed with CCLE based on clinical signs and compatible histopathological findings. MATERIALS AND METHODS: Oclacitinib was administered at the induction dosage of 0.45 mg/kg twice daily to 1.8 mg/kg once daily. The response to treatment was graded as ‘good’ when there was ≥50% lesion reduction, or as ‘complete remission’ if all active lesions had resolved. Complete blood counts were performed at variable intervals. RESULTS: A complete remission of all lesions was obtained in the dog with exfoliative cutaneous lupus erythematosus, both dogs with mucocutaneous lupus erythematosus and three of four dogs with facial discoid lupus erythematosus (FDLE); a good response was seen in the remaining dog with FDLE. The first visible improvement of signs was seen within 2‐to‐3 weeks, while the time to complete remission was around 2 months. Clinical adverse effects were not seen, and haematological parameters remained within the reference range. CONCLUSIONS AND CLINICAL RELEVANCE: Oclacitinib may be considered an effective treatment option for different variants of canine CCLE. John Wiley and Sons Inc. 2022-10-13 2023-02 /pmc/articles/PMC10092348/ /pubmed/36229964 http://dx.doi.org/10.1111/vde.13128 Text en © 2022 The Authors. Veterinary Dermatology published by John Wiley & Sons Ltd on behalf of ESVD and ACVD. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Auto‐immune and Immune‐Mediated Dermatoses Harvey, Richard G. Olivrī, Alla Lima, Tatiana Olivry, Thierry Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases |
title | Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases |
title_full | Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases |
title_fullStr | Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases |
title_full_unstemmed | Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases |
title_short | Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases |
title_sort | effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: seven cases |
topic | Auto‐immune and Immune‐Mediated Dermatoses |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092348/ https://www.ncbi.nlm.nih.gov/pubmed/36229964 http://dx.doi.org/10.1111/vde.13128 |
work_keys_str_mv | AT harveyrichardg effectivetreatmentofcaninechroniccutaneouslupuserythematosusvariantswithoclacitinibsevencases AT olivrialla effectivetreatmentofcaninechroniccutaneouslupuserythematosusvariantswithoclacitinibsevencases AT limatatiana effectivetreatmentofcaninechroniccutaneouslupuserythematosusvariantswithoclacitinibsevencases AT olivrythierry effectivetreatmentofcaninechroniccutaneouslupuserythematosusvariantswithoclacitinibsevencases |